Thomas Fuller | SOPA Photographs | Lightrocket | Getty Photographs
Pfizer mentioned on Monday it might purchase weight-loss drug developer Metsera in a deal valued as much as $7.3 billion, together with future funds, to safe its place within the profitable weight problems therapy market.
The worldwide weight problems drug market, projected to achieve $150 billion by the early 2030s, has boomed over the previous couple of years, pushed by the success of extremely efficient GLP-1-targeting therapies from firms resembling Novo Nordisk and Eli Lilly — each fiercely competing for market dominance.
Drugmakers have additionally been racing to develop next-generation therapies for weight problems, together with medicine that concentrate on different hormones and assist protect muscle whereas dropping fats, to ascertain their presence available in the market.
Pfizer CEO Albert Bourla mentioned Metsera’s acquisition “propels Pfizer into this key therapeutic space” and would leverage the corporate’s cardiometabolic experience and world infrastructure to speed up next-generation weight problems medicines.
The deal follows Pfizer’s current setbacks in its personal improvement efforts with weight-loss tablet danuglipron.
The corporate had scrapped the event of a once-a-day model of danuglipron in April after a trial affected person skilled potential drug-induced liver damage, which resolved after the medicine was stopped. It had discontinued the event of a twice-daily model in late 2023 as a result of varied uncomfortable side effects.
The newest deal might be a “significant constructive for Pfizer, positioning it with a extra sturdy weight problems pipeline that might be differentiated on dosing”, BMO Capital analyst Evan Seigerman mentioned.
Pfizer pays $47.50 per share in money to Metsera, representing a premium of about 43% to the New York-based firm’s final shut.
Metsera can also be eligible to obtain a further $22.50 per share contingent on the achievement of sure efficiency milestones. Its shares surged practically 60% to $53.16 in premarket buying and selling, whereas Pfizer was up about 2%.
The Monetary Instances had reported on the deal on Sunday.
